



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/619,685	07/15/2003	Hirohiko Hirochika	YAMZ 2 00005-2	8565
7590	05/09/2005			
			EXAMINER	
			KUBELIK, ANNE R	
			ART UNIT	PAPER NUMBER
			1638	
DATE MAILED: 05/09/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/619,685	HIROCHIKA ET AL.
Examiner	Art Unit	
Anne R. Kubelik	1638	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-4 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-4 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 - 1. Certified copies of the priority documents have been received.
 - 2. Certified copies of the priority documents have been received in Application No. 09/667,475.
 - 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: search results.

DETAILED ACTION

1. Claims 1-4 are pending.
2. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825.

Sequence identifiers are missing from pg 11, lines 31-33, pg 12, line 1, pg 13, lines 31-32, pg 14, lines 11, 18 and 31, and pg 15, lines 2, 4, 11 and 13.

Full compliance with the sequence rules is required in response to this Office action. A complete response to this Office action must include both compliance with the sequence rules and a response to the issues set forth herein. Failure to fully comply with both of these requirements in the time period set forth in this Office action will be held to be non-responsive.

Claim Objections

3. Claim 2 is objected to because of the recitation “The A” at the start of the claim.
4. Claims 2 and 4 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 1 is drawn to a nucleic acid encoding SEQ ID NO:2, wherein SEQ ID NO:2 controls leaf shapes; dependent claim 2, recites that the nucleic acid controls leaf shapes in a specific manner. Claim 2 fails to further limit claim 1 because a protein of SEQ ID NO:2 would inherently alter leaf shapes in that manner. Claim 4 similarly fails to further limit claim 3.

Claim Rejections - 35 USC § 112

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
6. Claims 1-4 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claims contain subject matter that was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The claims are broadly drawn to nucleic acids of SEQ ID NO:1 or that encode SEQ ID NO:2.

The instant specification only provides guidance for activation of the Tos17 retrotransposon in rice plants comprising that transposon (example 1), isolation of narrow-leaf mutants (example 2), linkage analysis to show that Tos17 was linked to the narrow-leaf mutation (example 3), isolation of the gene (SEQ ID NO:3) responsible for the narrow-leaf mutation by TAIL-PCR of Tos17 (example 3 and 4), and construction of a cDNA library and isolation of a cDNA (SEQ ID NO:1, which encodes SEQ ID NO:2) corresponding to the gene (example 4).

The instant specification fails to provide guidance for how to use nucleic acids of SEQ ID NO:1 or that encode SEQ ID NO:2.

Plants in which genes that control leaf shape are altered by mutation or genetic engineering have unpredictable phenotypes. Schneeberger et al (1998, Development 125:2857-2865) show that maize plants in which the *rough sheath2* gene is disrupted by a transposon had

leaf blade tissue transformed into sheath tissue and suggest that auxin homeostasis is disrupted in *rs2* mutants and in plants in which other homeodomain proteins are ectopically expressed (see pg 2860, right column, paragraph 2, and pg 2864, left column, paragraph 2). Hareven et al (1996, Cell 84:735-744) teach that ectopic expression of the *Knotted-1* gene affects simple and compound leaves in very different ways (pg 741, right column, paragraph 3, to pg 742, left column, paragraph 2). The instant specification suggests expressing SEQ ID NO:1 in a plant (see, e.g., pg 5, lines 16-17), but does not teach the effect overexpression would have on plants with different leaf structures; thus, one would not know how to use the invention.

The specification does not describe the transformation of any plant with a nucleic acid of SEQ ID NO:1 or that encodes SEQ ID NO:2, undue trial and error experimentation would be required to determine what, if any, effect this overexpression would have, and then determine how to sue such plants.

Given the claim breadth, unpredictability in the art, and lack of guidance in the specification as discussed above, the instant invention is not enabled throughout the full scope of the claims.

7. Claims 1-4 are free of the prior art, given the failure of the prior art to teach or suggest an isolated nucleic acid encoding SEQ ID NO:2. The closest prior art is a nucleic acid encoding a protein with 45.1% identity to SEQ ID NO:2 (Choisne et al, 2000, GenBank Accession No. T47895; see search results).

Conclusion

8. No claim is allowed.
9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am - 5:00 pm.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (571) 272-0804. The central fax number for official correspondence is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Anne R. Kubelik, Ph.D.
April 18, 2005



ANNE KUBELIK, PH.D.
PRIMARY EXAMINER